Eine Forscherin füllt ein Reagenzglas in einem Labor
Eine Forscherin füllt ein Reagenzglas in einem Labor

Our Science

Value of Science

The challenges of cancer can be relentless – but so are we. Our unwavering commitment to patients drives us to advance novel therapeutics that have the potential to address the needs of patients with difficult-to-treat cancers.

 

MorphoSys is dedicated to the advancement of promising oncology drug candidates. Our clinical development network has a proven track record of operational excellence with experience in numerous topline data analyses, regulatory submissions, and successful approvals, including at MorphoSys and others at previous pharmaceutical and biotech companies.

Together, we are paving the way for the future of oncology.

CLINICAL DEVELOPMENT

scientist-with-micrsoscope
scientist-with-micrsoscope

Our Pipeline

View our mid- to late-stage oncology pipeline and a selection of clinical programs developed by our partners via our legacy antibody technology.

MORPHOSYS’ CLINICAL PROGRAMS

Pelabresib

Pelabresib

Pelabresib is an investigational BET inhibitor being studied in myelofibrosis and other myeloid diseases.
 

Tulmimetostat

Tulmimetostat

Tulmimetostat is an investigational next-generation dual EZH2/EZH1 inhibitor being explored in solid tumors and lymphomas.

Standing person speaking to seated audience
Standing person speaking to seated audience

Medical Congresses

As part of scientific exchange, MorphoSys releases clinical data at medical congresses to show progress and maintain transparency.

Doctor speaking to patient
Doctor speaking to patient

Expanded Access Program (EAP)

Under certain circumstances, MorphoSys may provide access to investigational medicines outside of clinical trials in accordance with local health authorities and our EAP criteria.